| De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia A Hyrenius-Wittsten, M Pilheden, H Sturesson, J Hansson, MP Walsh, ... Nature Communications 9 (1), 1770, 2018 | 43 | 2018 |
| Anti‐tumor effects of PIM/PI 3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma S Mohlin, K Hansson, K Radke, S Martinez, C Blanco‐Apiricio, ... EMBO molecular medicine 11 (8), e10058, 2019 | 42 | 2019 |
| CRISPR to fix bad blood: a new tool in basic and clinical hematology E González-Romero, C Martínez-Valiente, C García-Ruiz, ... haematologica 104 (5), 881, 2019 | 40 | 2019 |
| A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic … A Liquori, I Lesende, L Palomo, G Avetisyan, M Ibáñez, ... Cancers 13 (8), 1947, 2021 | 9 | 2021 |
| Aberrant Alternative Splicing in U2af1/Tet2 Double Mutant Mice Contributes to Major Hematological Phenotypes C Martínez-Valiente, C Garcia-Ruiz, B Rosón, A Liquori, ... International journal of molecular sciences 22 (13), 6963, 2021 | 6 | 2021 |
| Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice C Garcia-Ruiz, C Martínez-Valiente, L Cordón, A Liquori, ... Leukemia 36 (10), 2509-2518, 2022 | 3 | 2022 |
| FLT3 N676K drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis A Hyrenius-Wittsten, M Pilheden, A Falqués-Costa, M Eriksson, ... Leukemia 33 (9), 2310-2314, 2019 | 3 | 2019 |
